Novo Nordisk's reports to the FDA spiked shortly after an inspection found the Ozempic producer ignored reports of deaths and potential side effects.

Officials wrote that Novo Nordisk had failed to failed to report ‘serious and unexpected’ adverse drug experiences ...

Right now, the drugs come with a hefty price tag. Ozempic typically runs 8,800 to 11,000 rupees ($95–$119) per month, while ...

Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, Wegovy and ...

The patent on semaglutide, found in Novo Nordisk's Ozempic and Wegovy weight-loss drugs, expired in India on March 20. Vikrant Shrotriya, managing director at Novo Nordisk India, talks about how ...

Hims & Hers Health has agreed to stop selling compound versions of Novo Nordisk’s Wegovy and other weight-loss drugs, ending ...

Novo Nordisk stock fell over 16% Monday after it said its next-generation weight loss drug didn't meet its primary target.

Novo Nordisk said Tuesday it will slash its prices for Wegovy and Ozempic beginning next year by up to 50%, highlighting the growing competition among pharmaceutical firms for customers seeking weight ...

Thin is in. With both the health brigade and fad nudging people towards weight-loss drugs, the market could soon be flooded ...

Novo Nordisk is slashing the list prices of its flagship weight-loss and diabetes drugs, including Wegovy and Ozempic, by up to 50% in the U.S., starting Jan. 1, 2027. The move is designed to improve ...

The agreement brings an end to the legal dispute between the two companies. Hims & Hers shares jumped.

With Novo Nordisk's semaglutide patent expiring, Indian pharmaceutical companies are poised to launch affordable generic versions of Ozempic and Wegovy, promising a significant price drop in ...